Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689484 | 0.84 | CA1 (0.61) | RELACA1CA2CA12CA14 | |
| SCHEMBL608990 | 0.84 | CA1 (0.61) | RELACA1CA2CA12CA14 | |
| SCHEMBL27317514 | 0.84 | RELA (0.55) | RELACA1CA2CA12CA14 | |
| SCHEMBL6044984 | 0.83 | RELA (0.59) | RELACA1CA2CA12CA14 | |
| Hydrochloric Acid SCHEMBL6245274 | 0.81 | RELA (0.62) | RELACA1CA2CA12CA14 | |
| SCHEMBL14081714 | 0.80 | RELA (0.81) | RELACA1CA2PPARAEPHX1 | |
| SCHEMBL29098369 | 0.80 | RELA (0.81) | RELACA1CA2PPARAEPHX1 | |
| SCHEMBL7687766 | 0.80 | RELA (0.66) | RELACA1CA2CA12CA14 | |
| SCHEMBL3369161 | 0.79 | RELA (0.70) | RELACA1CA2PPARA | |
| SCHEMBL277303 | 0.79 | CA1 (0.67) | RELACA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1266118-C | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2006-07-26 | — | — | CN | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| CN-1550491-A | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | ��˹��ŵ�� | 2004-12-01 | — | — | CN | disclosed |
| CN-1153759-C | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | ��˹��ŵ�� | 2004-06-16 | — | — | CN | disclosed |
| WO-2003103653-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| CN-1117960-A | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | CN | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | RELA 1191/4885CA1 221/4885CA2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.